EU Archives -

Market Access/ News/ News

CHMP backs Amicus’ therapy for Pompe disease

Phil Taylor Amicus Therapeutics, CHMP, EU, Galafold, Pombiliti, Pompe disease, rare disease 0 Comment

Amicus Therapeutics could be just weeks away from getting EU approval for its new Pompe disease therapy Pombiliti

CHMP backs Amicus’ therapy for Pompe disease

https://pharmaphorum.com/news/chmp-backs-amicus-therapy-for-pompe-disease/

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

Market Access/ News/ News/ News/ Oncology

AZ’s Imfinzi/Imjudo combo backed in EU for liver, lung cancers

Phil Taylor AstraZeneca, CHMP, Enhertu, EU, Imfinzi, Imjudo, immuno-oncology, Oncology 0 Comment

AstraZeneca’s oncology portfolio continues to deliver, with a recommendation for EU approval of its new Imfinzi/Imjudo immunotherapy combination

AZ’s Imfinzi/Imjudo combo backed in EU for liver, lung cancers

https://pharmaphorum.com/news/azs-imfinzi-imjudo-combo-backed-in-eu-for-liver-lung-cancers/

Market Access/ News/ News/ News/ Sales and Marketing

CSL closes on EU approval for haemophilia B gene therapy

Phil Taylor CHMP, CSL, EU, gene therapy, haemophilia B, Hemgenix, uniQure 0 Comment

CSL’s gene therapy for haemophilia B has been recommended for approval by the EMA’s human medicine committee, setting

CSL closes on EU approval for haemophilia B gene therapy

https://pharmaphorum.com/news/csl-closes-on-eu-approval-for-haemophilia-b-gene-therapy/

Helsinki_University _Hospital_cancer_care

Digital/ News/ News/ News/ Oncology

EU launches AI-powered real-world data project for cancer therapies

Phil Taylor digital, digital health, EU, Health Technology Assessment, HEOR, Horizon Europe programme, Oncology 0 Comment

The European Commission has provided around €7 million ($7.2 million) in funding to a new project that aims

EU launches AI-powered real-world data project for cancer therapies

https://pharmaphorum.com/news/eu-launches-ai-powered-real-world-data-project-for-cancer-therapies/

Digital/ News/ News

EMA unveils first projects as data partners join DARWIN EU project

Phil Taylor big data, DARWIN, digital, digital health, ema, EU, real world data, Real World Evidence 0 Comment

Two years ago, the EMA proposed a set of recommendations to unlock the potential of big data for

EMA unveils first projects as data partners join DARWIN EU project

https://pharmaphorum.com/news/ema-unveils-first-projects-as-data-partners-join-darwin-eu-project/

Cancer/ Events/ Insights/ Oncology/ Views and analysis/ World Cancer Series

Economist Impact: World Cancer Series – pharmaphorum in attendance, day one (part ii)

Nicole Raleigh BECA, cancer care, Cancer Research UK, Economist Impact, EU, Government of Malta, Innovation, MSD Italy, prevention, The Economist, World Cancer Series 0 Comment

To continue with pharmaphorum’s coverage of Day One of The Economist’s 8th Annual World Cancer Series congress in

Economist Impact: World Cancer Series – pharmaphorum in attendance, day one (part ii)

https://pharmaphorum.com/views-and-analysis/economist-impact-world-cancer-series-pharmaphorum-in-attendance-day-one-part-ii/

Market Access/ News/ News/ News/ Sales and Marketing

AstraZeneca’s Tezspire for severe asthma gets green light in EU

Phil Taylor Amgen, asthma, AstraZeneca, EU, regulatory approval, severe asthma, Tezspire 0 Comment

The European Commission has followed the lead of the US FDA and approved AstraZeneca’s Tezspire as an add-on

AstraZeneca’s Tezspire for severe asthma gets green light in EU

https://pharmaphorum.com/news/astrazenecas-tezspire-for-severe-asthma-gets-green-light-in-eu/

Market Access/ News/ News

Otsuka, Aurinia claim EU okay for oral lupus nephritis drug

Phil Taylor Aurinia, EU, Lupkynis, lupus, lupus nephritis, Otsuka, regulatory approval 0 Comment

Aurinia Pharma and partner Otsuka have secured approval in the EU for Lupkynis, billed as the first oral

Otsuka, Aurinia claim EU okay for oral lupus nephritis drug

https://pharmaphorum.com/news/otsuka-aurinia-claim-eu-okay-for-oral-lupus-drug/

News/ News/ Sales and Marketing

Novartis probed by Swiss authorities over ‘unlawful’ patent use

Phil Taylor antitrust, EU, Financial, Novartis, patent, regulatory, switzerland 0 Comment

The competition authorities in Switzerland said this morning they have carried out a raid on a pharma company

Novartis probed by Swiss authorities over ‘unlawful’ patent use

https://pharmaphorum.com/news/novartis-probed-by-swiss-authorities-over-unlawful-patent-use/

Trending

EU

Login